title: Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.
abstract: Cancer immunotherapy (CIT) initiates or enhances the host immune response against cancer. Following decades of development, patients with previously few therapeutic options may now benefit from CIT. Although the quantitative clinical pharmacology (qCP) of previous classes of anticancer drugs has matured during this time, application to CIT may not be straightforward since CIT acts via the immune system. Here we discuss where qCP approaches might best borrow or start anew for CIT.
authors.affiliation: Department of Clinical Pharmacology, Genentech South San Francisco, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Stroh
authors.affiliation: Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Welwyn, UK.
authors.forename: D J
authors.initials: DJ
authors.lastname: Carlile
authors.affiliation: Department of Clinical Pharmacology, Genentech South San Francisco, California, USA.
authors.forename: C-C
authors.initials: CC
authors.lastname: Li
authors.affiliation: Roche Innovation Center Basel Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Wagg
authors.affiliation: Roche Innovation Center Basel Switzerland.
authors.forename: B
authors.initials: B
authors.lastname: Ribba
authors.affiliation: Department of Preclinical and Translational PKPD, Genentech South San Francisco, CA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Ramanujan
authors.affiliation: Department of Clinical Pharmacology, Genentech South San Francisco, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Jin
authors.affiliation: Department of Clinical Pharmacology, Genentech South San Francisco, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.affiliation: Roche Innovation Center Basel Switzerland.
authors.forename: J-E
authors.initials: JE
authors.lastname: Charoin
authors.affiliation: Roche Innovation Center New York New York, USA.
authors.forename: Z-X
authors.initials: ZX
authors.lastname: Xhu
authors.affiliation: Department of Preclinical and Translational PKPD, Genentech South San Francisco, CA, USA.
authors.forename: P N
authors.initials: PN
authors.lastname: Morcos
authors.affiliation: Department of Clinical Pharmacology, Genentech South San Francisco, California, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Davis
authors.affiliation: Department of Clinical Pharmacology, F. Hoffmann-La Roche, Roche Innovation Center Welwyn, UK.
authors.forename: A
authors.initials: A
authors.lastname: Phipps